NASDAQ:OSRH

OSR Q2 2025 Earnings Report

OSR logo
$0.35 -0.01 (-2.77%)
As of 11:24 AM Eastern
This is a fair market value price provided by Massive. Learn more.

OSR EPS Results

Actual EPS
$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

OSR Revenue Results

Actual Revenue
$1.14 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OSR Announcement Details

Quarter
Q2 2025
Time
During Market Hours
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

OSR Earnings Headlines

25-Cent Gold Explorer Set to Drill Top Canadian Mineral Belt
With gold racing toward US$5,000 an ounce, one sub-$0.25 explorer is launching a fully funded drill campaign on an already large gold discovery in one of Canada's most mining-friendly jurisdictions. The company controls a multi-million-ounce gold system with multiple high-priority targets and a strong treasury to support aggressive exploration. Multiple catalysts are stacked for 2H 2026 and beyond - at a market cap that still reflects very little of the potential.tc pixel
See More OSR Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OSR? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OSR and other key companies, straight to your email.

About OSR

OSR (NASDAQ:OSRH) Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

View OSR Profile